GNG5 and prostate carcinoma: Combining the database information of TCGA and GTEx for analysis, we found that the mRNA levels of GNG5 were upregulated in most cancers; these include hepatocellular carcinoma, bile duct cancer, colon cancer, lung cancer, pancreatic cancer, gastric cancer, thyroid cancer, adrenocortical cancer, prostate cancer, and breast cancer.